*Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.1
†In patients who are not transplant candidates.1
‡Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.1
§Lower-risk MF is defined as low or intermediate-1 risk based on DIPSS, DIPSS-Plus, and MYSEC-PM; low or intermediate risk based on MIPSS-70 (threshold of ≤3 prognostic variable points); and very low, low, or intermediate risk based on MIPSS-70+ Version 2.0 (threshold of ≤3 prognostic variable points).1
DIPSS=Dynamic International Prognostic Scoring System; MIPSS=Mutation-enhanced International Prognostic Score System; MYSEC-PM=myelofibrosis secondary to PV and ET-prognostic model; NCCN=National Comprehensive Cancer Network.
Jakafi is indicated for treatment of intermediate or high-risk MF, including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed January 5, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.